News | August 08, 2022
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Dr Sai Satish, Sr. Consultant Interventional Cardiologist performs India’s first 3 successful G4-Transcatheter Edge to Edge (G4–TEER) mitral valve repairs
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Manish led SeQuent since 2014 and played a major role in transforming the company
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
Advancing to IND-enabling studies with multiple drug candidates
Syngene's collaboration with Zoetis started in 2011
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
